Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer patients may soon skip hospital trips for skin rashes thanks to telemedicine

NCT ID NCT07476807

Symptom relief Sponsor: Sligo General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether video consultations can safely assess and manage skin rashes caused by cancer treatments. Researchers will enroll 25 adult cancer patients with mild skin toxicity and see if telemedicine works as well as in-person visits. The goal is to reduce hospital visits while keeping care effective and safe.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
telemedicine assessment
What this could lead to
If successful, this could offer a convenient way for cancer patients to get skin issues checked from home, reducing hospital trips.
What could go wrong
This is a very small pilot study (25 people) with no comparison group, so results may not apply widely. Video assessments might miss serious problems that need in-person care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 25 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria:Participants must meet all of the following criteria: * Adult oncology or haematology patients currently receiving systemic anti-cancer therapy (SACT). * New-onset dermatologic toxicity consistent with a recognised adverse effect of the administered SACT. * Skin toxicity severity graded ≤ Grade 2 in accordance with UKONS assessment criteria. * Clinically stable condition not requiring urgent in-person evaluation. * Access to, and ability to use, a smartphone or computer with adequate internet connectivity to participate in telemedicine consultations. Exclusion Criteria: Participants will be excluded if any of the following criteria apply: * Skin toxicity graded ≥ Grade 3 according to UKONS assessment criteria. * Clinical status requiring urgent or immediate face-to-face medical assessment. * Dermatologic toxicity that is atypical, unexpected, or not consistent with known SACT-related adverse effects. * Inability to access or effectively use the required telemedicine technology.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rash are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

exanthem

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rash Systemic treatments Tele-assessment

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sligo university Hospital

    Sligo, Sligo, f91h684, Ireland